Inactive Instrument

HUTCHISON CHINA MED. Stock London S.E.

Equities

Pharmaceuticals

Sales 2024 * 685M Sales 2025 * 843M Capitalization 3.27B
Net income 2024 * -96M Net income 2025 * 6M EV / Sales 2024 * 4.3 x
Net cash position 2024 * 323M Net cash position 2025 * 352M EV / Sales 2025 * 3.46 x
P/E ratio 2024 *
-34.9 x
P/E ratio 2025 *
223 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 56.05%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on HUTCHISON CHINA MED.

Managers TitleAgeSince
Chief Executive Officer 66 04-12-31
Director of Finance/CFO 57 08-06-30
Chief Tech/Sci/R&D Officer 59 21-12-31
Members of the board TitleAgeSince
Director/Board Member 73 17-02-28
Chairman 70 16-07-31
Director/Board Member 71 99-12-31
More insiders
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Calendar
More about the company